Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Empagliflozin reduced risk of death and hospitalisation for heart failure by 25 per cent in adults

expresspharmaAugust 31, 2020

Tag: Empagliflozin , Heart failure , Boehringer Ingelheim , Diabetes

PharmaSources Customer Service